171 related articles for article (PubMed ID: 3531332)
1. Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow.
Merluzzi VJ; Trail PA; Last-Barney K
J Immunol; 1986 Oct; 137(8):2425-7. PubMed ID: 3531332
[TBL] [Abstract][Full Text] [Related]
2. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous alloreactivity of natural killer (NK) and lymphokine-activated killer (LAK) cells from athymic rats against normal haemic cells. NK cells stimulate syngeneic but inhibit allogeneic haemopoiesis.
Rolstad B; Benestad HB
Immunology; 1991 Sep; 74(1):86-93. PubMed ID: 1937576
[TBL] [Abstract][Full Text] [Related]
5. Influence of T cells on the expression of lymphokine-activated killer cell activity and in vivo tissue distribution.
Maghazachi AA; Goldfarb RH; Herberman RB
J Immunol; 1988 Dec; 141(11):4039-46. PubMed ID: 2846699
[TBL] [Abstract][Full Text] [Related]
6. Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases.
Sherwood ER; Williams DL; McNamee RB; Jones EL; Browder IW; Di Luzio NR
J Biol Response Mod; 1988 Apr; 7(2):185-98. PubMed ID: 3283299
[TBL] [Abstract][Full Text] [Related]
7. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
8. Lymphokine-activated killer cells are generated before classical cytotoxic T lymphocytes after bone marrow transplantation in mice.
Merluzzi VJ; Savage DM; Smith MD; Last-Barney K; Mertelsmann R; Moore MA; Welte K
J Immunol; 1985 Sep; 135(3):1702-6. PubMed ID: 3894518
[TBL] [Abstract][Full Text] [Related]
9. Role of lymphokine-activated killer cells as mediators of veto and natural suppression.
Azuma E; Kaplan J
J Immunol; 1988 Oct; 141(8):2601-6. PubMed ID: 3171179
[TBL] [Abstract][Full Text] [Related]
10. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
11. Identification of macromolecular insoluble cold globulin (MICG) as a new marker shared by NK and ADCC cells, but not expressed by NC cells.
Campos-Perera C; Murgita RA; Hauptman SP; Gronvik KO
Immunology; 1986 Sep; 59(1):101-7. PubMed ID: 2428732
[TBL] [Abstract][Full Text] [Related]
12. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
13. Separation of lymphokine-activated killer cell precursors and T-cells: differential growth characteristics and apparent lack of a T-cell suppressor of LAK-cell induction.
Rinehart JJ; Geidenberger C; Aldrich W
Mol Biother; 1989; 1(3):133-9. PubMed ID: 2532518
[TBL] [Abstract][Full Text] [Related]
14. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
Long GS; Cramer DV; Harnaha JB; Hiserodt JC
Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
[TBL] [Abstract][Full Text] [Related]
16. Generation of natural killer cells from bone marrow precursors in vitro.
Kalland T
Immunology; 1986 Apr; 57(4):493-8. PubMed ID: 3485566
[TBL] [Abstract][Full Text] [Related]
17. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells activated with interleukin 2 in vitro can be adoptively transferred and mediate hematopoietic histocompatibility-1 antigen-specific bone marrow rejection in vivo.
Murphy WJ; Kumar V; Bennett M
Eur J Immunol; 1990 Aug; 20(8):1729-34. PubMed ID: 2209686
[TBL] [Abstract][Full Text] [Related]
19. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
20. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
